Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | GAPDH | P04406 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774950 | 0.89 | ADORA3 (0.67) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL20995821 | 0.87 | MEN1 (0.66) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL29406864 | 0.87 | MEN1 (0.66) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL658714 | 0.87 | MEN1 (0.66) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL658713 | 0.87 | MEN1 (0.66) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL29409681 | 0.86 | MEN1 (0.65) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL31000830 | 0.85 | MEN1 (0.56) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL29771414 | 0.84 | ADORA1 (0.56) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL1059414 | 0.84 | ADORA1 (0.56) | MEN1KMT2AADORA1ADORA3SLC29A1 | |
| SCHEMBL887800 | 0.84 | ADORA1 (0.56) | MEN1KMT2AADORA1ADORA3SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624387-B2 | Method for reducing primer dimer formation and increasing amplification efficiency | SEEGENE, INC. (KR) | 2026-05-12 | — | — | US | claimed |
| US-12371736-B2 | TD probe and its uses | SEEGENE, INC. (KR) | 2025-07-29 | — | — | US | claimed |
| EP-4293127-A2 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | Seegene, Inc. (KR) | 2023-12-20 | — | — | EP | claimed |
| EP-4001428-B1 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | SEEGENE INC (KR) | 2023-11-22 | — | — | EP | claimed |
| CN-110168103-B | Methods for reducing primer dimer formation and increasing amplification efficiency | SEEGENE株式会社 | 2023-09-08 | — | — | CN | claimed |
| EP-4001428-A1 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | Seegene, Inc. (KR) | 2022-05-25 | — | — | EP | claimed |
| EP-3562958-B1 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | SEEGENE INC (KR) | 2021-11-03 | — | — | EP | claimed |
| US-10870675-B2 | Process using dual specificity oligonucleotide and dual specificity oligonucleotide | SEEGENE, INC. (KR) | 2020-12-22 | — | — | US | claimed |
| US-20190316193-A1 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | SEEGENE, INC. (KR) | 2019-10-17 | — | — | US | claimed |
| US-20180141970-A1 | PROCESS USING DUAL SPECIFICITY OLIGONUCLEOTIDE AND DUAL SPECIFICITY OLIGONUCLEOTIDE | SEEGENE, INC. (KR) | 2018-05-24 | — | — | US | claimed |
| US-9884890-B2 | Process using dual specificity oligonucleotide and dual specificity oligonucleotide | SEEGENT, INC. (KR) | 2018-02-06 | — | — | US | claimed |
| EP-2365078-B1 | Processes using dual specificity oligonucleotide and dual specificity oligonucleotide | SEEGENE INC (KR) | 2013-11-20 | — | — | EP | claimed |
| US-20130090464-A1 | Process Using Dual Specificity Oligonucleotide and Dual Specificity Oligonucleotide | SEEGENE, INC. (KR) | 2013-04-11 | — | — | US | claimed |
| US-8192940-B2 | Method for amplifying unknown DNA sequence adjacent to known sequence | SEEGENE, INC. (KR) | 2012-06-05 | — | — | US | claimed |
| US-8058032-B2 | Method for amplifying unknown DNA sequence adjacent to known sequence | SEEGENE, INC. (KR) | 2011-11-15 | — | — | US | claimed |
| EP-2365078-A1 | Processes using dual specificity oligonucleotide and dual specificity oligonucleotide | Seegene, Inc. (KR) | 2011-09-14 | — | — | EP | claimed |
| US-20090298128-A1 | Method for Amplifying Unknown DNA Sequence Adjacent to Known Sequence | SEEGENE, INC. (KR) | 2009-12-03 | — | — | US | claimed |
| US-20080305478-A1 | Processes Using Dual Specificity Oligonucleotide and Dual Specificity Oligonucleotide | SEEGENE, INC. (KR) | 2008-12-11 | — | — | US | claimed |
| US-20260134944-A1 | COMPUTER-IMPLEMENTED METHOD FOR PROVIDING ALIGNMENT INFORMATION ABOUT OLIGONUCLEOTIDE SEQUENCE FOR TARGET NUCLEIC ACID SEQUENCE | SEEGENE, INC. (KR) | 2026-05-14 | — | — | US | disclosed |
| WO-1999018238-A1 | COMBINATORIAL ANTISENSE LIBRARY | OASIS BIOSCIENCES, INC. (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090464-A1 | Process Using Dual Specificity Oligonucleotide and Dual Specificity Oligonucleotide | CPSF7, CPSF6, MTHFD2 | MEN1 3137/4885KMT2A 2358/4885ADORA1 4060/4885 |
| US-12624387-B2 | Method for reducing primer dimer formation and increasing amplification efficiency | UBR4, UBAP2, UBAP2L | MEN1 4336/4885KMT2A 2920/4885ADORA1 4726/4885 |
| US-20260134944-A1 | COMPUTER-IMPLEMENTED METHOD FOR PROVIDING ALIGNMENT INFORMATION ABOUT OLIGONUCLEOTIDE SEQUENCE FOR TARGET NUCLEIC ACID SEQUENCE | PCNA, POLN, MCTS1 | MEN1 185/4885KMT2A 918/4885ADORA1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.